Immunosuppressive and calcimimetic drug-drug interactions [8]

Kidney International

Volumn 68, Issue 4, 2005, Pages 1903-1904

  Izzedine, Hassane ^a,b   Launay Vacher, Vincent ^a   Karie, Svetlana ^a   Deray, Gilbert ^a  

^a Pitie Salpetriere Hospital ^*

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIMIMETIC AGENT; CINACALCET; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

CALCIUM BLOOD LEVEL; HUMAN; HYPERPARATHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LETTER; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; NAPHTHALENES;

EID: 31644434042     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00578_8.x     Document Type: Letter

References (5)

1. FIJN R, VAN DEN BEMT PM, CHOW M, et al: Hospital prescribing errors: Epidemiological assessment of predictors. Br J Clin Pharmacol 53:326-331, 2002
2. CLASSEN DC, PESTOTNIK SL, EVANS RS, et al: Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277:301-306, 1997
3. BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
4. AMGEN, INC.: Cinacalcet (Sensipar®) US prescribing information (online). Available at: http://www.sensipar.com. Accessed May 27, 2005
5. THERVET E, LEGENDRE C, BEAUNE P, ANGLICHEAU D: Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 6:37-47, 2005